Impel Neuropharma Signs $100 Million Royalty and Debt Financing Agreement


Shares of U.S. CNS-focused pharmaceutical company Impel NeuroPharma (Nasdaq:IMPL) rose 5.3% to $6.98 in early afternoon trading, after hitting $7.24, after announcing two separate transactions with funds managed by Oaktree Capital Management, totaling $100 million in gross funding. .

The transactions include a $50 million royalty agreement on net sales of migraine nasal spray, Trudhesa (dihydroergotamine mesylate), and $50 million of senior secured debt.…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.

Source link


About Author

Comments are closed.